4c04999ea5a87968ebc.sjV4VgeRdRKpP9WkoGyfOaliubgMM-uY-1dN28ILTbo.gn9JZFDFD1WEcZn08ijAbtoq2v5-eYXLnmF97aRZJdv0ZEEgSdwMVNpl7Q
09-10 Biocorrx Inc Announces Appointment of Richard J. Baum to Strategic Advisory Board CI
09-04 BioCorRx Inc. Announces Resignation of Kate Beebe Devarney as Member of the Board of Directors, Effective August 31, 2026 CI
08-14 BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-31 BioCorRx Inc. Auditor Raises 'Going Concern' Doubt CI
01-06 BioCorRx Inc. Announces Board Changes, Effective January 1, 2026 CI
12-10 BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th AQ
11-15 BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
14/08/25 BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
29/07/25 BioCorRx Inc. announced that it has received $0.35 million in funding CI
16/05/25 BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
31/03/25 BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
31/03/25 BioCorRx Inc. Auditor Raises 'Going Concern' Doubt CI
14/11/24 BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
15/08/24 BioCorRx Reports Business Update for the Second Quarter of 2024 AQ
14/08/24 BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
16/05/24 BioCorRx Reports Business Update for the First Quarter of 2024 AQ
15/05/24 BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04/04/24 BioCorRx Inc. Announces Board Resignations CI
03/04/24 BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia AQ
02/04/24 BioCorRx Reports Business Update for 2023 AQ
02/04/24 BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01/04/24 BioCorRx Inc. Auditor Raises 'Going Concern' Doubt CI
28/02/24 BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD AQ

Become a member to access more news

New member
No results match your criteria